Showing results (41-50 of 81) with videos related to

Sort By:
Pageof 9
Cancers|May 14, 2022
Azacitidine vs. Decitabine in Unfit Newly Diagnosed Acute Myeloid Leukemia Patients: Results from the PETHEMA RegistryJorge Labrador, David Martínez-Cuadrón, Adolfo de la Fuente, et al.
Haematologica|August 10, 2023
Feasibility and outcomes after dose reduction of immunochemotherapy in young adults with Burkitt lymphoma and leukemia: results of the BURKIMAB14 trialJosep-Maria Ribera, Mireia Morgades, Olga Garcia-Calduch, et al.
American Journal of Hematology|February 11, 2026
Intensive Chemotherapy With or Without Midostaurin in Adults ≥ 60 Years Old With FLT3-Mutated AML: A FILO-DATAML-PETHEMA Real-World StudyGaspar Aspas Requena, Pau Montesinos, Emilie Bérard, et al.
Disease Markers|September 2, 2022
No Evidence that CD33 rs12459419 Polymorphism Predicts Gemtuzumab Ozogamicin Response in Consolidation Treatment of Acute Myeloid Leukemia Patients: Experience of the PETHEMA GroupTamara Castaño-Bonilla, Eva Barragán, Claudia Sargas, et al.
Cancers|June 2, 2021
The Mutational Landscape of Acute Myeloid Leukaemia Predicts Responses and Outcomes in Elderly Patients from the PETHEMA-FLUGAZA Phase 3 Clinical TrialRosa Ayala, Inmaculada Rapado, Esther Onecha, et al.
Cancers|December 11, 2022
Impact of FLT3-ITD Mutation Status and Its Ratio in a Cohort of 2901 Patients Undergoing Upfront Intensive Chemotherapy: A PETHEMA Registry StudyRosa Ayala, Gonzalo Carreño-Tarragona, Eva Barragán, et al.
Leukemia Research|April 3, 2020
Performance of prognostic scoring systems in elderly patients with acute myeloid leukaemia on intensive chemotherapy: A PETHEMA registry studyCarlos Rodríguez-Medina, David Martínez-Cuadrón, Isabel Cano, et al.
Clinical Lymphoma, Myeloma & Leukemia|April 28, 2020
Treatment of Frail Older Adults and Elderly Patients With Philadelphia Chromosome-negative Acute Lymphoblastic Leukemia: Results of a Prospective Trial With Minimal ChemotherapyJosep-Maria Ribera, Olga García, Eduardo Cerello Chapchap, et al.
Cancer|February 24, 2021
A phase 3 trial of azacitidine versus a semi-intensive fludarabine and cytarabine schedule in older patients with untreated acute myeloid leukemiaSusana Vives, David Martínez-Cuadrón, Juan Bergua Burgues, et al.
Blood Cancer Journal|May 12, 2023
Comparison of the 2022 and 2017 European LeukemiaNet risk classifications in a real-life cohort of the PETHEMA groupClaudia Sargas, Rosa Ayala, María J Larráyoz, et al.
Pageof 9